Eli Lilly's $2.6 billion agreement with ABL Bio focuses on developing therapeutics using the Grabody Platform for bispecific ...

The new generation of obesity medications are inducing greater weight loss than any prior pharmacotherapy. There is discussion now about how to support fat loss while protecting lean mass.“Lean mass ...

Novo Nordisk is rated a 'Strong Buy' due to its undervaluation, wide economic moat, and long-term growth prospects despite ...

Discover why Recursion Pharmaceuticals, Inc. stands out in AI drug discovery, but faces valuation risks. Click for my look at ...

Major stock indexes ended sharply lower to begin the week, which will see AI darling Nvidia and retail giants report ...

As he discussed Amgen, it was unsurprising that weight loss drug giant Eli Lilly and Company (NYSE:LLY) also caught Cramer’s ...

Dow Jones Top Company Headlines at 7 AM ET: Home Depot Cuts Outlook As Home Improvement Slowdown Continues | Roche ... Home Depot reported lower third-quarter profit and lowered its full-year outlook ...

Here’s what else you need to know to get up to speed and on with your day. 1️⃣ Border Patrol. Border Patrol agents have ...

The shift shows up clearly in market valuations. At the end of March 2024, Novo Nordisk was worth over $500 billion and Lilly ...

Right now, that's none other than Eli Lilly (NYSE: LLY). However, others are looking to challenge its dominance. Recent comments from Pfizer 's (NYSE: PFE) CEO, Albert Bourla, suggest it could become ...

Eli Lilly and Company (NYSE: LLY) is one of the 15 Best Aggressive Growth Stocks to Buy Right Now. On November 7, TD Cowen ...

The introduction of AbbVie’s hepatitis C drugs in 2014 forced Gilead’s hand in the fight for market dominance in hepatitis C.